Dimerix Secures A$34M Non-Dilutive Loan to Fund Kidney Disease Trials
Melbourne – September 08, 2026 -- Dimerix Limited (ASX: DXB) has secured non-dilutive loan facility agreements worth up to A$34 million with a syndicate of Australian and U.S. lenders, expanding on its previously announced A$10 million SKIPTAN facility.
Dimerix locks in A$34 million loan facility from Australian, U.S. lenders
The new terms are substantially consistent with the earlier SKIPTAN agreement, with minor amendments made to standardise conditions across all lenders. The structure gives Dimerix the option to expand total commitments to A$50 million on or before March 31, 2027, though the company currently has no plans to draw on that additional capacity.